文献速递胸部肿瘤

罕见肺部肿瘤的综合基因组分析:腺鳞癌与肺癌肉瘤

Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma.
PubMed 文献 · J Thorac Oncol · 2025-07-26

本文综述了罕见肺部肿瘤腺鳞癌(ASC)和肺癌肉瘤(PC)的分子特征,包括基因组、转录组及免疫治疗替代生物标志物,以拓展对这些罕见肿瘤的认识并加速新疗法开发。

要点

  • 罕见肺部肿瘤ASC和PC的分子图谱数据不足,限制了靶向和免疫治疗的应用。
  • 本文提供了ASC和PC的基因组、转录组及免疫治疗预测生物标志物的综合分子分析数据。
  • 这些数据旨在拓展对罕见肿瘤的认识并加速新疗法的研发。

核心结论

  • 罕见肺部肿瘤ASC和PC的分子特征数据不足,亟需积累知识以指导靶向治疗和免疫治疗。

研究设计与样本

  • 与Caris Life Sciences合作,展示ASC和PC的基因组、转录组及免疫治疗替代生物标志物的分子分析数据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In 2025, lung cancer remains the leading cause of cancer-related mortality in both men and women. Although the advent of immunotherapy and targeted therapies has revolutionized the treatment of NSCLC, treatments for rare histologic types such as adenosquamous carcinoma and pulmonary carcinosarcoma remain limited owing to insufficient data on molecular profiling. As such, knowledge of the molecular characteristics of rare tumors to inform treatment modalities for targeted approaches is desperately needed. In collaboration with Caris Life Sciences, we present new molecular profiling data including genomic, transcriptomic, and the current landscape of surrogate biomarkers to predict response to immunotherapy for ASC and PC to aid in expanding knowledge of these rare tumors and expediting novel therapies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou T, Terry OC, Minton KG, et al. Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma. J Thorac Oncol. 2025. PMID: 40721085. doi:10.1016/j.jtho.2025.07.122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。